Grant Details
Grant Number: |
1R01CA268004-01A1 Interpret this number |
Primary Investigator: |
Posluszny, Donna |
Organization: |
University Of Pittsburgh At Pittsburgh |
Project Title: |
Dyadic Intervention to Improve Patient-Family Caregiver Team-Based Management of the Medical Regimen After Allogenetic Hematopoietic Cell Transplantation |
Fiscal Year: |
2022 |
Abstract
ABSTRACT
Allogeneic hematopoietic cell transplantation (HCT) can be a lifesaving treatment for patients with
hematologic disease. It is also one of the most life-altering treatments, given the high risks of morbidity and
mortality, and requiring extensive commitments of money, time, and effort. Following a protracted inpatient stay
and initial successful engraftment of healthy cells, patients return to their homes where they must follow a
complex medical regimen that requires the help of a family caregiver to reduce their risk of infection and other
threats to long term treatment success. Adherence to the regimen by the patient and family caregiver,
however, is a significant clinical problem. Evidence-based interventions to help patients and their family
caregivers manage the many challenges of the post-HCT regimen together are urgently needed but have
received little research attention. To address this need, we have developed a dyadic problem-solving therapy
(DPST-HCT) intervention to help HCT patients and their family caregivers manage the post-HCT medical
regimen as a team. The planned research will make use of a combination of qualitative and quantitative
methods iteratively within a user-centered design approach to refine the intervention and provide evidence of
acceptability, feasibility, and efficacy. In Stage 1, we will conduct focus groups and incorporate patient, family
caregiver, and health care professional feedback on medical management challenges and the usefulness of
the intervention. In Stage 2, we will interatively refine the intervention with a small number of patient-family
caregiver dyads, resulting in a finalized intervention. In Stage 3, we will evaluate the final version of the DPST-
HCT in a single-site randomized controlled trial to determine acceptability, feasibility, and efficacy. We will
randomize 104 newly transplanted allogeneic HCT patient-family caregiver dyads (N=208) to the DPST-HCT
arm or Enhanced Usual Care comparison arm and assess study outcomes at 1-, 5-, 12-, and 24-weeks post-
intervention completion. We will (a) determine process considerations (acceptability, feasibility); (b) provide an
initial test of intervention efficacy on primary outcomes (dyadic team-based management: adherence and self-
efficacy), and secondary outcomes (patient and family caregiver well-being, perceived health, health-related
quality of life, patient clinical events, and patient health care utilization. Anticipated results will provide further
support for a dyadic team-based approach to post HCT medical regimen management and serve as the basis
for a multi-site RCT to test DPST-HCT.
Publications
None